Evidence map›Paper›PMID 41825097›Full record

ArticleJHEP reports : innovation in hepatology2026

Single-photon emission computed tomography functional liver imaging to facilitate reirradiation for liver malignancies: A phase I trial.

Enoch Chang, Emma B Holliday, Janio Szklaruk, William D Erwin, Ethan B Ludmir, Sonal S Noticewala, Prajnan Das, Albert C Koong, Bruce D Minsky, Grace L Smith and 25 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02626312 (Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02626312 phase1terminatednot on this map

Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2016 to 2026Enrolled36ConditionsCholangiocarcinoma, Cirrhosis, Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the LiverArmsLaboratory Biomarker Analysis, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Enoch ChangDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Emma B HollidayDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Janio SzklarukDepartment of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
William D ErwinDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ethan B LudmirDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sonal S NoticewalaDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Prajnan DasDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Albert C KoongDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bruce D MinskyDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Grace L SmithDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Gabriel O SawakuchiDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rachael M Martin-PaulpeterDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joshua S NiedzielskiDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luis A PerlesDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sam BeddarDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Veronica S ValinoDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joshua L NguyenDepartment of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kanwal P S RaghavDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Milind JavleDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ahmed O KasebDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Arvind N DasariDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael J OvermanDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Christine M ParseghianDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bruno C OdisioDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Armeen MahvashDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Joshua D KubanDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shu-En ShenDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xin S WangDepartment of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aashish C GuptaDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mais M Al TaieDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kristy K BrockDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ching-Wei D TzengDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jean-Nicolas VautheyDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Franklin C L WongDepartment of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Eugene J KoayDepartment of Gastrointestinal Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ekoay@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Optimization and Evaluation of Anatomical Models of Liver Radiation ResponseR01CA221971 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BROCK, KRISTY · 2018 to 2022
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA221971
6 · The paper itself

Abstract

BACKGROUND &

aimsThis phase I trial evaluated the safety of hypofractionated liver reirradiation (reRT) with preferential sparing of functional liver identified by technetium-99m sulfur colloid single-photon emission computed tomography (Tc-99m SC SPECT; hereafter SPECT) for patients previously treated with external beam radiotherapy or transarterial radioembolization.

methodsA 3+3 design evaluated the safety of two escalating SPECT-based functional liver volumetric dose constraints. Dose-limiting toxicities (DLTs), liver segment volumes, and MRI functional liver imaging score, relative liver enhancement, and elastography were assessed.

resultsThirteen patients were enrolled from 2018 to 2021. Median reRT gross tumor volume was 61 cm

conclusionsSPECT may facilitate safe reRT for liver tumors. IMPACT AND IMPLICATIONS: Although ablative liver-directed radiotherapy confers excellent local control rates for patients with hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and liver metastases, recurrence in the previously uninvolved liver occurs in 50-70% of cases, and retreatment is often challenging given the risk of radiation-induced liver disease. We conducted a phase I trial investigating hypofractionated liver reRT after previous external beam radiotherapy or transarterial radioembolization, which was safely facilitated with the aid of SPECT functional liver imaging, to preferentially identify and spare functional liver. Compensatory liver hypertrophy was observed, and dynamic quantitative MRI biomarkers were associated with functional liver changes. Thus, the incorporation of advanced functional imaging techniques could help expand retreatment options for patients with limited remaining hepatic reserve. CLINICAL TRIALS REGISTRATION: the study is registered at ClinicalTrials.gov (NCT02626312).

Indexed as

Liver cancersPhase I trialQuantitative imaging biomarkersReirradiationSPECT

Identifiers

PMID41825097
PMCPMC12995903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.